Slowing the progression of Alzheimer’s disease; what works?

Nelson, Lucy; Tabet, Naji

doi:10.1016/j.arr.2015.07.002

Cited by 84 publications

(70 citation statements)

References 260 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4 To date, no effective treatments are available to ameliorate or cure AD, the most common neurodegenerative cause of cognitive impairment. However, some research suggests that treating vascular risk factors and performing cognitively stimulating activities may delay the onset of cognitive impairment 5 and reduce AD pathology. 6 Exposure to complex, stimulating neighborhood environments may be one mechanism that delays cognitive impairment.…”

Section: Contextmentioning

confidence: 99%

Neighborhood Environment and Cognition in Older Adults: A Systematic Review

Besser

McDonald

Song

et al. 2017

American Journal of Preventive Medicine

160

148

View full text Add to dashboard Cite

Context Some evidence suggests that treating vascular risk factors and performing mentally stimulating activities may delay cognitive impairment onset in older adults. Exposure to a complex neighborhood environment may be one mechanism to help delay cognitive decline. Evidence acquisition PubMed, Web of Science, and ProQuest Dissertation and Theses Global database were systematically reviewed, identifying 25 studies published from February 1, 1989 to March 5, 2016 (data synthesized, May 3, 2015–October 7, 2016). The review restricted to quantitative studies focused on: (1) neighborhood social and built environment and cognition; and (2) community-dwelling adults aged ≥45 years. Evidence synthesis The majority of studies were cross-sectional, U.S.-based, and found at least one significant association. The diversity of measures and neighborhood definitions limited the synthesis of findings in many instances. Evidence was moderately strong for an association between neighborhood SES and cognition and modest for associations between neighborhood demographics, design, and destination accessibility and cognition. Most studies examining effect modification found significant associations, with some evidence for effect modification of the neighborhood SES–cognition association by individual-level SES. No studies had low risk of bias and many tested multiple associations that increased the chance of a statistically significant finding. Considering the studies to date, the evidence for an association between neighborhood characteristics and cognition is modest. Conclusions Future studies should include longitudinal measures of neighborhood characteristics and cognition, examine potential effect modifiers such as sex and disability, and study mediators that may help elucidate the biological mechanisms linking neighborhood environment and cognition.

show abstract

Section: Contextmentioning

confidence: 99%

Neighborhood Environment and Cognition in Older Adults: A Systematic Review

Besser

McDonald

Song

et al. 2017

American Journal of Preventive Medicine

160

148

View full text Add to dashboard Cite

show abstract

“…There are no currently FDA-approved pharmacological treatments for NPS in the setting of neurocognitive disorders, but there is a body of evidence that explores distinct pharmacological approaches for different NPS [77]. The HTA-SADD trial demonstrated no difference between sertraline or mirtazapine and placebo with respect to efficacy though there were higher numbers of drug-related adverse events [78].…”

Section: Neuropsychiatric Symptoms Of Dementia (Neurocognitive Disordmentioning

confidence: 98%

Psychiatric and Medical Comorbidity in the Primary Care Geriatric Patient—An Update

Kennedy

Castro

Chang

et al. 2016

Curr Psychiatry Rep

View full text Add to dashboard Cite

The mental health needs of older primary care patients are now widely recognized if not widely addressed. The range of behavioral health approaches including co-locating psychiatrists and integrating mental health professionals as care managers into primary care sites is extensive and growing. Nonetheless the primary care provider remains the first line of defense against mental disorders, most commonly depression and anxiety that accompany and exacerbate common physical conditions. The excess, potentially avoidable disability that results from comorbidity makes it imperative that early recognition and evidence based intervention occur. Multi-morbidity and polypharmacy make intervention a challenge. Psychotherapy can help overcome comorbidity depression however the most accessible intervention would be an antidepressant FDA approved for both anxiety and depressive disorders. For all these reasons, a focus on physical conditions most commonly associated with mental disorders can foster early recognition before the older patient's care becomes overwhelmingly complicated.

show abstract

“…‐Anti‐inflammatory: reduces NF‐κB, TNF‐α, and COX‐2 signalling pathways and inhibits IL‐8, Il‐6, IL‐1β and IL‐1α production via inhibition of the MAPK and NF‐κB pathways (Ghosh et al, ; Nelson & Tabet, )…”

Section: Phytochemicals As Nutraceuticalsmentioning

confidence: 99%

Role of phytochemicals as nutraceuticals for cognitive functions affected in ageing

Howes

Perry²,

Vásquez-Londoño

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Cognitive decline can occur with normal ageing and in age‐related brain disorders, such as mild cognitive impairment and dementia, including Alzheimer's disease, with limited pharmacological therapies available. Other approaches to reduce cognitive decline are urgently needed, and so, the role of dietary interventions or nutraceuticals has received much attention in this respect. In this review, we examine the evidence for dietary plants and their chemical constituents as nutraceuticals, relevant to both cognitive decline in normal ageing and in dementia. Pharmacological (in vitro and in vivo), clinical and epidemiological evidence is assessed for both frequently consumed plants and their dietary forms, including tea, coffee, cocoa (chocolate), red wine, grapes, citrus and other fruits; in addition to plants used less frequently in certain diets and those that cross the blurred boundaries between foods, nutraceuticals and medicinal plants. For the latter, turmeric, saffron, sage, rosemary and lemon balm are examples of those discussed. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Slowing the progression of Alzheimer’s disease; what works?

Cited by 84 publications

References 260 publications

Neighborhood Environment and Cognition in Older Adults: A Systematic Review

Neighborhood Environment and Cognition in Older Adults: A Systematic Review

Psychiatric and Medical Comorbidity in the Primary Care Geriatric Patient—An Update

Role of phytochemicals as nutraceuticals for cognitive functions affected in ageing

Contact Info

Product

Resources

About